GlassScriptPhysician profile
Amy Chao
NPI 1083881882
$2,744.08
in general payments reported to CMS, 2019-2025
22 companies · $513 in 2025
The $513 reported for 2025 was more than what 77% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
See the full distribution for Acute Care (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $323 · 2022: $680 · 2023: $565 · 2024: $664 · 2025: $513.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,742.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,741.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $597.36 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $562.20 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $248.89 | 2022-2024 | Jardiance |
| Alnylam Pharmaceuticals INC. | $195.45 | 2025 | Amvuttra |
| Janssen Pharmaceuticals, INC | $175.52 | 2021-2024 | Xarelto |
| Amgen INC. | $168.43 | 2021-2025 | Repatha |
| Boston Scientific Corporation | $154.11 | 2022-2024 | Watchman Access System, Varithena Administration Pack |
| Astellas Pharma US INC | $114.79 | 2021-2023 | Lexiscan |
| E.R. Squibb & Sons, L.L.C. | $106.54 | 2022-2024 | Camzyos, Eliquis |
| Actelion Pharmaceuticals US, INC. | $70.62 | 2021-2022 | |
| Inspire Medical Systems, INC. | $54.08 | 2024 | Inspire |
| Lexicon Pharmaceuticals, INC. | $48.69 | 2023 | Inpefa |
| Abiomed | $44.05 | 2025 | |
| Merck Sharp & Dohme LLC | $35.08 | 2023-2024 | Verquvo |
| Heartflow, INC. | $32.59 | 2025 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $22.19 | 2021 | |
| Novo Nordisk INC | $21.07 | 2023 | Rybelsus, Ozempic |
| Sobi, INC | $20.95 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $19.76 | 2023 | Wainua |
| Scpharmaceuticals INC. | $18.83 | 2023 | |
| Kiniksa Pharmaceuticals, LTD. | $17.70 | 2022 | |
| Glaxosmithkline, LLC. | $15.18 | 2025 | Arexvy, Shingrix |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Chao listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.